Article Text

Download PDFPDF
EP1267 Assessment of efficacy of post-operative triptorelin in improving pain symptoms from deep infiltrating endometriosis: a 24-month multicentre, prospective, non-interventional study in highest pain intensity patient population
  1. X Zhang1,
  2. V Perrot2 and
  3. H Li3
  1. 1Zhejiang University, Hangzhou, China
  2. 2Ipsen Pharma, Boulogne-Billancourt, France
  3. 3Ipsen (Beijing) Pharmaceutical Science and Technology Development Co., Ltd., Beijing, China


Introduction/Background Symptom recurrence in patients with deep infiltrating endometriosis (DIE) undergoing conservative surgery is common. Adjuvant use of gonadotropin-releasing hormone agonists (e.g. triptorelin, IPSEN Pharma) can improve postoperative pain caused by DIE and prolong the asymptomatic period. This analysis from a multicentre, non-interventional, observational study (NCT01942369) assessed the effect of triptorelin administration on the most severe intensity symptoms reported by the patient.

Methodology This study included patients with DIE aged ≥18 years who underwent conservative surgical treatment within 1 month before inclusion and were prescribed triptorelin (3.75 mg) as part of their treatment for up to 24 weeks. The intensity of symptoms was assessed using a 10-cm visual analogue scale (VAS) or numerical scale ranging from 0 to 10 at baseline and 3, 6, 9, 12, 18 and 24 months. At baseline (pre-surgery assessment), the most severe intensity for all the symptoms reported by the patient was identified, and changes in selected symptoms’ intensity were assessed. Paired t-test was used to assess the change in intensity.

Results In total, 384 patients (mean ± standard deviation [SD] age: 33.4±6.2 years) were included. Among the symptoms identified with the most severe intensity at baseline, dysmenorrhea (69.5%), pelvic pain (28.9%) and dyspareunia (13.8%) were most frequently reported. At baseline, the mean (SD) VAS scores for pelvic pain (n=111), dysmenorrhea (n=267) and dyspareunia (n=53) were 5.25 (3.11), 6.32 (3.06) and 3.68 (3.09) cm, respectively, which significantly decreased at all-time points (mean VAS decrease <1 cm, P<0.0001 for all). Irrespective of the number of injections, the mean VAS score of these three symptoms significantly decreased from baseline (P<0.05).

Conclusion This observational study confirmed that postoperative triptorelin administration was beneficial in women with DIE suffering from the highest pain intensity. However, individualised treatment for optimal pain relief needs to be further addressed.

Disclosure This study was sponsored by Ipsen. The authors declare the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Valerie Perrot and Hongbo Li are employees of Ipsen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.